Odefsey FDA Approval History
FDA Approved: Yes (First approved March 1, 2016)
Brand name: Odefsey
Generic name: emtricitabine, rilpivirine and tenofovir alafenamide
Dosage form: Tablets
Company: Gilead Sciences, Inc.
Treatment for: HIV Infection
Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) is a fixed-dose combination of emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV nucleoside analog reverse transcriptase inhibitors (NRTIs), and rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), indicated as a complete regimen for the treatment of HIV-1 infection.
Development timeline for Odefsey
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.